ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act By Ogkologos - June 11, 2025 483 0 Facebook Twitter Google+ Pinterest WhatsApp Ensuring equitable access to cancer treatments remains central to EU health security efforts Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR From athlete to wig-maker: how cancer changed Maria’s destiny December 16, 2022 Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare... July 26, 2023 With Longer Follow-Up, Trastuzumab Deruxtecan Continues to Demonstrate Superior Efficacy Over... June 27, 2024 Hormone Therapy Can Put Cancer Cells Into Sleep Mode And Cause... November 12, 2019 Load more HOT NEWS Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients... Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... 9 Ways to Use Social Media for Support Throughout Your Cancer...
